Kathryn M. McNeil
Keine laufenden Positionen mehr
Karriereverlauf von Kathryn M. McNeil
Ehemalige bekannte Positionen von Kathryn M. McNeil
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
INVITAE CORPORATION | Public Communications Contact | 01.04.2017 | 01.04.2018 |
CELLECTAR BIOSCIENCES, INC. | Investor Relations Kontakt | 01.10.2013 | 28.07.2015 |
Public Communications Contact | 01.10.2013 | 28.07.2015 | |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | Investor Relations Kontakt | 13.11.2013 | 12.02.2014 |
Public Communications Contact | 13.11.2013 | 12.02.2014 | |
CHELSEA THERAPEUTICS INTERNATIONAL LTD. | Investor Relations Kontakt | - | - |
Public Communications Contact | - | - |
Ausbildung von Kathryn M. McNeil
Wesleyan University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 6 |
Operativ
Public Communications Contact | 4 |
Investor Relations Contact | 3 |
Undergraduate Degree | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 2 |
Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
CELLECTAR BIOSCIENCES, INC. | Health Technology |
INVITAE CORPORATION | Health Services |
Private Unternehmen | 2 |
---|---|
Chelsea Therapeutics International Ltd.
Chelsea Therapeutics International Ltd. BiotechnologyHealth Technology Chelsea Therapeutics International Ltd. acquires, develops and commercializes innovative products for the treatment of a variety of human diseases. The company was founded by Simon C. Pedder on June 17, 2005 and is headquartered in Charlotte, NC. | Health Technology |
Novelos Therapeutics, Inc.
Novelos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI. | Health Technology |
- Börse
- Insiders
- Kathryn M. McNeil
- Erfahrung